Compare DexCom, Inc. (DXCM) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs CarMax, Inc — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while CarMax, Inc trades at $58.5 (market cap $8.26B). The key difference: DexCom, Inc. is far larger — about 4.1× CarMax, Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | KMX | |
|---|---|---|
Market Cap | $33.79B | $8.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $62.17 |
52-Week Low | $54.84 | $30.88 |
Enterprise Value | $33.24B | $26.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
CarMax (KMX) trades at $58.705, down 0.13% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, missing in Q2 2025 but beating in Q3 2025 and Q1 2026, with net income of $500.56M in 2025. Recent news includes a Zacks Strong Buy rating and a partnership with Sierra to enhance customer service, though ongoing legal investigations pose a headwind.
The stock's outlook is cautiously optimistic, supported by improving cash flow trends and analyst buy ratings, but risks include high debt levels and margin pressures. With a consensus price target of $53.09 below the current price, near-term upside may be limited despite positive momentum indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
